• FastWave Medical

  Led · Equity · Nov 2025

  FastWave Medical is a Brooklyn Park, Minnesota–based medtech startup creating a surgical device intended to simplify and improve procedures for patients with severe arterial disease. Co-founded and led by CEO Scott Nelson, the company’s core product is still under development; specific clinical or commercial metrics have not yet been disclosed. In 2021 the company secured a $12 million strategic investment from China-based Grand Pharmaceutical Group to advance its R&D and regulatory pathway. Since that financing, Grand Pharmaceutical has withheld further capital and declined to cooperate with a required regulatory filing that would let FastWave bring in new investors. As a result, FastWave is now navigating that regulatory process on its own while fielding interest from additional backers. Nelson has also expressed concern that Grand’s parallel investment in a Chinese firm developing similar technology could jeopardize FastWave’s intellectual property and competitive position. The company’s immediate focus is resolving the legal hurdles so it can reopen fundraising and continue product development toward clinical and commercial milestones.

• Xeltis

  Participated · Series D · Aug 2023

  Xeltis develops implantable vascular and cardiovascular devices based on its Restorex® platform, which uses an advanced polymer implant that transforms into the patient’s own tissue and is gradually absorbed. Its lead product, aXess™, is an implantable blood vessel for hemodialysis vascular access that has received CE Mark approval and is being commercially deployed in Europe. The company is enrolling a US pivotal trial of aXess™ (now >50% enrolled) and is preparing for FDA submission and a US market launch. Xeltis plans to use recent funding to support European commercial rollout, upscale manufacturing and advance its XABG and XPAD clinical programs. Financially, the company raised €50m in 2025 from the European Investment Bank and existing shareholders and added €20.5m in 2026 from new and existing investors to fund its next phase of clinical, regulatory and commercial execution.

• Isotopen Technologien München

  Led · Equity · Feb 2022

  ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech based in Garching, Germany focused on advancing radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. Its lead candidate is n.c.a. 177Lu-edotreotide (ITM-11 / 177Lu-edotreotide), and the company supports a broad precision oncology pipeline including multiple Phase 3 studies. The company is led by CEO Dr. Andrew Cavey. ITM plans to use new capital to prepare for commercial readiness and potential market launch of its lead candidate. The company announced a non-dilutive debt financing agreement that will support late-stage development and commercial preparation. ITM is a radiopharmaceutical biotech company dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. Led by CEO Steffen Schuster and based in Munich, Germany, the company focuses on advancing radiopharmaceutical candidates. ITM intends to use the funds to advance and expand its radiopharmaceutical pipeline and to foster its development platform. The company will prepare commercial readiness for the potential market launch of its phase III lead candidate, ITM-11 (n.c.a. 177Lu-edotreotide), for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Proceeds will also enable expansion of manufacturing capabilities for production of alpha- and beta-emitting radioisotopes, including Lutetium-177(177Lu) and Actinium-225(225Ac). ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech focused on radiomolecular precision therapeutics and diagnostics (theranostics) and a broad Targeted Radionuclide Therapies (TRT) oncology pipeline. Its lead candidate ITM-11 (n.c.a. 177Lu-edotreotide) is nearing the final stages of phase III development in gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and ITM-31 (Lu-177 labeled 6A10 Fab-fragments) is in clinical studies for glioblastoma. The company is also a major radioisotope supplier and is expanding manufacturing and GMP capabilities for n.c.a. 177Lu and scaling GMP manufacturing for 225Ac to meet growing demand. Planned investments include a second state-of-the-art manufacturing facility in Germany, expanded in-house drug product manufacturing, and broader commercial infrastructure to accelerate global access. ITM has opened a U.S. headquarters in Princeton, New Jersey and established a subsidiary in Shanghai to support regional introduction of precision oncology products. The company says it will leverage nearly two decades of radiopharma expertise and its global network to improve patient access to targeted treatments. ITM develops targeted radiopharmaceutical diagnostics and therapeutics by combining medical radioisotopes with targeting molecules to treat hard-to-treat cancers. The company produces and supplies high-quality medical radioisotopes through a wide-reaching international supply network and leverages nearly two decades of radiopharma expertise. Its lead therapeutic candidate, ITM-11 (n.c.a. 177Lu-edotreotide), is being evaluated in two phase III trials (COMPETE and COMPOSE) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM plans to use recent financing to finalize late-stage development of ITM-11, support potential commercialization and market launch efforts if approved, accelerate development of additional radiopharmaceutical candidates, and expand radioisotope supply capabilities. The company emphasizes precision oncology approaches that deliver radiation directly to tumors while minimizing exposure to healthy tissue. ITM is positioned as a global player in nuclear medicine, aiming to advance a broad proprietary pipeline and enable wider clinical adoption of targeted radionuclide therapies. ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech company focused on development, production and global supply of targeted radionuclide diagnostics and therapeutics. The company produces high-quality medical radioisotopes and leverages nearly two decades of radiopharma expertise and an established global supply network. ITM has forward-integrated to build a broad pipeline, including lead candidate ITM-11 (n.c.a. 177Lu-edotreotide) which is undergoing two phase III trials (COMPETE and COMPOSE), and companion diagnostic TOCscan® (68Ga-edotreotide). ITM-41 (n.c.a. 177Lu-zoledronate) is in preclinical development for osteosarcoma and bone metastases. The company is focused on expanding its presence in Asia and Greater China to meet growing patient needs. A recent strategic equity investment is intended to support late-stage development and broader commercialization efforts in the region.

• InnovHeart

  Led · Series C · Jan 2022

  InnovHeart s.r.l. develops Transcatheter Mitral Valve Replacement (TMVR) systems to treat mitral valve disease, notably its Saturn low-profile mitral heart valve designed for trans-apical or trans-septal delivery. The company has reported excellent mid-term (>1 year) results with the trans-apical version of Saturn and is conducting clinical trials of the system. InnovHeart intends to advance a trans-septal version of the Saturn system into first-in-human clinical trials in 2022. In January 2022 it closed a Series C financing tied to an exclusive licensing agreement in Greater China. The transaction included more than $55 million in equity plus upfront licensing fees, milestone payments and structured royalties to support development and commercialization. InnovHeart has locations in Milan, Italy and Newton, Massachusetts, USA. InnovHeart develops the Saturn transcatheter mitral valve replacement (TMVR) system, a low-profile mitral heart valve designed for trans‑apical and trans‑septal delivery. The company is advancing its Saturn system toward First‑in‑Human clinical evaluation using a trans‑apical approach. Proceeds from the recent financing will also support finalizing the trans‑septal delivery system that uses the same valve technology. InnovHeart maintains offices outside Milan, Italy, and in Newton, Massachusetts. The company was founded in 2015 and has been conducting clinical trials of its Saturn TMVR system. Leadership highlights include board chair Keith D. Dawkins, MD, and the addition of Barbara Castellano to the board representing an investor.

• Corisma

  Led · Series A · Aug 2021

  CoRISMA is a stage medical device company based in New Haven, CT, spun out of the Bonde Artificial Heart Lab at Yale and founded in 2018. The company has advanced a transcatheter, implantable cardiac treatment device that features wirelessly powered mechanical circulatory support. CoRISMA is led by CEO Mike Theran and Pramod Bonde. The company raised $27M in a Series A to accelerate development and expand availability of its cardiac treatment device. The financing is intended to support product development and broader availability efforts. No operating metrics or revenue figures were disclosed in the article.

No current team members are available.